CARL SPANA, Ph.D.
President and Chief Executive Officer
Dr. Spana, co-founder of Palatin, has served as president and chief executive officer since 2000. He has been a director of Palatin since 1996 and has been a director of Palatin’s wholly-owned subsidiary, RhoMed Incorporated, since 1995. From 1996 to 2000, Dr. Spana served as an executive vice president and chief technical officer of Palatin.
From 1993 to 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From 1991 to 1993, Dr. Spana was a research associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology.
Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
STEPHEN T. WILLS, C.P.A., M.S.T.
Chief Financial Officer and Chief Operating Officer
Mr. Wills joined Palatin as vice president and chief financial officer in 1997. He brings a depth of financial experience in public accounting and healthcare to the company.
From 1991 to 2000, Mr. Wills served as the president and chief operating officer of Golomb, Wills and Company, P.C., a public accounting firm. During that time, from 1997 to 2000, he was also the vice president and chief financial officer of Derma Sciences, Inc., a publicly-held company providing wound and skin care products. Mr. Wills is currently lead director of Derma Sciences.
Mr. Wills, a certified public accountant, earned his B.S. in accounting from West Chester University, and an M.S. in taxation from Temple University.
JOHNA LUCAS, M.A., M.D., F.A.C.O.G.
Chief Medical Officer
Dr. Lucas is Chief Medical Officer of Palatin and medical director of Palatin's reconnect studies, parallel Phase 3 studies on bremelanotide for hypoactive sexual desire disorder (HSDD).
Dr. Lucas, who is a Fellow of The American Congress of Obstetricians and Gynecologists, is author on a number of scientific papers on HSDD and other female sexual disorders. After joining industry in 1999, she was responsible for the clinical development and medical affairs of Intrinsa, a testosterone transdermal system for the treatment of HSDD for Procter & Gamble Pharmaceuticals, was a Senior Medical Director for Warner Chilcott Ltd., a specialty pharmaceutical company acquired by Actavis plc in late 2013, and lead pharmacovigilance activities for several products for Bristol-Myers Squibb Pharmaceutical Company. Prior to this she was the Chairman of Gynecology at the Cleveland Clinic Florida.
Dr. Lucas received her M.D. and M.A. from University of Missouri, Columbia and did residency and fellowship training at Case-Western Reserve University Hospitals in Cleveland, Ohio.